Annual CFO
-$155.01 M
-$19.66 M-14.53%
December 31, 2023
Summary
- As of February 7, 2025, BTAI annual cash flow from operations is -$155.01 million, with the most recent change of -$19.66 million (-14.53%) on December 31, 2023.
- During the last 3 years, BTAI annual CFO has fallen by -$88.66 million (-133.62%).
- BTAI annual CFO is now -11878.83% below its all-time high of -$1.29 million, reached on December 31, 2016.
Performance
BTAI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$16.34 M
+$6.84 M+29.50%
September 30, 2024
Summary
- As of February 7, 2025, BTAI quarterly cash flow from operations is -$16.34 million, with the most recent change of +$6.84 million (+29.50%) on September 30, 2024.
- Over the past year, BTAI quarterly CFO has increased by +$10.53 million (+39.18%).
- BTAI quarterly CFO is now -4973.91% below its all-time high of -$322.00 thousand, reached on September 30, 2017.
Performance
BTAI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$84.08 M
+$21.25 M+20.17%
September 30, 2024
Summary
- As of February 7, 2025, BTAI TTM cash flow from operations is -$84.08 million, with the most recent change of +$21.25 million (+20.17%) on September 30, 2024.
- Over the past year, BTAI TTM CFO has increased by +$70.92 million (+45.76%).
- BTAI TTM CFO is now -19408.35% below its all-time high of -$431.00 thousand, reached on March 31, 2017.
Performance
BTAI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
BTAI Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.5% | +39.2% | +45.8% |
| 3 y3 years | -133.6% | +19.1% | -1.9% |
| 5 y5 years | -1047.4% | -118.3% | -210.3% |
BTAI Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.7% | at low | at high | +68.8% | -2.4% | +49.6% |
| 5 y | 5-year | -472.0% | at low | -106.3% | +68.8% | -210.3% | +49.6% |
| alltime | all time | <-9999.0% | at low | -4973.9% | +68.8% | <-9999.0% | +49.6% |
BioXcel Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.34 M(-29.5%) | -$84.08 M(-20.2%) |
| Jun 2024 | - | -$23.17 M(+30.9%) | -$105.33 M(-12.5%) |
| Mar 2024 | - | -$17.71 M(-34.1%) | -$120.36 M(-22.4%) |
| Dec 2023 | -$155.01 M(+14.5%) | -$26.86 M(-28.5%) | -$155.01 M(-7.1%) |
| Sep 2023 | - | -$37.58 M(-1.6%) | -$166.78 M(+4.0%) |
| Jun 2023 | - | -$38.21 M(-27.0%) | -$160.38 M(+3.3%) |
| Mar 2023 | - | -$52.35 M(+35.5%) | -$155.28 M(+14.7%) |
| Dec 2022 | -$135.34 M(+64.7%) | -$38.64 M(+23.9%) | -$135.34 M(+16.0%) |
| Sep 2022 | - | -$31.19 M(-5.8%) | -$116.63 M(+10.4%) |
| Jun 2022 | - | -$33.10 M(+2.1%) | -$105.65 M(+11.3%) |
| Mar 2022 | - | -$32.41 M(+62.6%) | -$94.93 M(+15.5%) |
| Dec 2021 | -$82.15 M(+23.8%) | -$19.93 M(-1.3%) | -$82.15 M(-0.4%) |
| Sep 2021 | - | -$20.20 M(-9.8%) | -$82.49 M(+1.3%) |
| Jun 2021 | - | -$22.38 M(+14.0%) | -$81.39 M(+10.2%) |
| Mar 2021 | - | -$19.64 M(-3.1%) | -$73.83 M(+11.3%) |
| Dec 2020 | -$66.35 M | -$20.27 M(+6.1%) | -$66.35 M(+22.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$19.10 M(+28.9%) | -$54.00 M(+27.4%) |
| Jun 2020 | - | -$14.82 M(+21.9%) | -$42.38 M(+26.2%) |
| Mar 2020 | - | -$12.16 M(+53.5%) | -$33.59 M(+23.9%) |
| Dec 2019 | -$27.10 M(+100.6%) | -$7.92 M(+5.8%) | -$27.10 M(+15.2%) |
| Sep 2019 | - | -$7.49 M(+24.2%) | -$23.52 M(+22.4%) |
| Jun 2019 | - | -$6.03 M(+6.3%) | -$19.22 M(+5.8%) |
| Mar 2019 | - | -$5.67 M(+30.6%) | -$18.17 M(+34.5%) |
| Dec 2018 | -$13.51 M(+515.2%) | -$4.34 M(+36.3%) | -$13.51 M(+31.6%) |
| Sep 2018 | - | -$3.19 M(-35.9%) | -$10.27 M(+38.7%) |
| Jun 2018 | - | -$4.97 M(+391.1%) | -$7.40 M(+166.5%) |
| Mar 2018 | - | -$1.01 M(-7.8%) | -$2.78 M(+26.5%) |
| Dec 2017 | -$2.20 M(+69.7%) | -$1.10 M(+241.0%) | -$2.20 M(+100.0%) |
| Sep 2017 | - | -$322.00 K(-6.7%) | -$1.10 M(+41.5%) |
| Jun 2017 | - | -$345.00 K(-20.0%) | -$776.00 K(+80.0%) |
| Mar 2017 | - | -$431.00 K | -$431.00 K |
| Dec 2016 | -$1.29 M | - | - |
FAQ
- What is BioXcel Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual CFO year-on-year change?
- What is BioXcel Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly CFO year-on-year change?
- What is BioXcel Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM CFO year-on-year change?
What is BioXcel Therapeutics annual cash flow from operations?
The current annual CFO of BTAI is -$155.01 M
What is the all time high annual CFO for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual cash flow from operations is -$1.29 M
What is BioXcel Therapeutics annual CFO year-on-year change?
Over the past year, BTAI annual cash flow from operations has changed by -$19.66 M (-14.53%)
What is BioXcel Therapeutics quarterly cash flow from operations?
The current quarterly CFO of BTAI is -$16.34 M
What is the all time high quarterly CFO for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly cash flow from operations is -$322.00 K
What is BioXcel Therapeutics quarterly CFO year-on-year change?
Over the past year, BTAI quarterly cash flow from operations has changed by +$10.53 M (+39.18%)
What is BioXcel Therapeutics TTM cash flow from operations?
The current TTM CFO of BTAI is -$84.08 M
What is the all time high TTM CFO for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM cash flow from operations is -$431.00 K
What is BioXcel Therapeutics TTM CFO year-on-year change?
Over the past year, BTAI TTM cash flow from operations has changed by +$70.92 M (+45.76%)